Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov;21(6):1246-1257.
doi: 10.1002/pst.2234. Epub 2022 May 19.

Standard and reference-based conditional mean imputation

Affiliations

Standard and reference-based conditional mean imputation

Marcel Wolbers et al. Pharm Stat. 2022 Nov.

Abstract

Clinical trials with longitudinal outcomes typically include missing data due to missed assessments or structural missingness of outcomes after intercurrent events handled with a hypothetical strategy. Approaches based on Bayesian random multiple imputation and Rubin's rules for pooling results across multiple imputed data sets are increasingly used in order to align the analysis of these trials with the targeted estimand. We propose and justify deterministic conditional mean imputation combined with the jackknife for inference as an alternative approach. The method is applicable to imputations under a missing-at-random assumption as well as for reference-based imputation approaches. In an application and a simulation study, we demonstrate that it provides consistent treatment effect estimates with the Bayesian approach and reliable frequentist inference with accurate standard error estimation and type I error control. A further advantage of the method is that it does not rely on random sampling and is therefore replicable and unaffected by Monte Carlo error.

Keywords: estimands; longitudinal data; reference-based imputation.

PubMed Disclaimer

Conflict of interest statement

Bartlett's institution has received consultancy fees for the author's advice on statistical methodology from AstraZeneca, Bayer, Novartis, and Roche. Bartlett has received consultancy and course fees from Bayer and Roche.

References

    1. ICH E9 Working Group . ICH E9 (R1): Addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials; 2019. https://database.ich.org/sites/default/files/E9‐R1_Step4_Guideline_2019_.... Accessed May 16, 2022.
    1. Mallinckrodt CH, Lane PW, Schnell D, Peng Y, Mancuso JP. Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials. Drug Inf J. 2008;42(4):303‐319.
    1. Mallinckrodt CH, Bell J, Liu G, et al. Aligning estimators with estimands in clinical trials: putting the ICH E9 (R1) guidelines into practice. Ther Innov Regul Sci. 2020;54(2):353‐364. - PubMed
    1. Cro S, Morris TP, Kenward MG, Carpenter JR. Sensitivity analysis for clinical trials with missing continuous outcome data using controlled multiple imputation: a practical guide. Stat Med. 2020;39(21):2815‐2842. - PubMed
    1. Polverejan E, Dragalin V. Aligning treatment policy estimands and estimators—a simulation study in Alzheimer's disease. Stat Biopharm Res. 2020;12(2):142‐154.

Publication types

LinkOut - more resources